BlackRock
KYTX icon

BlackRock’s Kyverna Therapeutics KYTX Stock Holding History

BlackRock’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Buy
3,134,807
+2,257,729
+257% +$20M ﹤0.01% 3046
2026
Q1 		$7.57M Buy
877,078
+332,539
+61% +$2.77M ﹤0.01% 3659
2025
Q4 		$5.12M Buy
544,539
+62,485
+13% +$464K ﹤0.01% 3831
2025
Q3 		$2.89M Sell
482,054
-51,413
-10% -$206K ﹤0.01% 3981
2025
Q2 		$1.64M Sell
533,467
-1,142,801
-68% -$2.83M ﹤0.01% 4120
2025
Q1 		$3.24M Buy
1,676,268
+3,775
+0.2% +$11.2K ﹤0.01% 3814
2024
Q4 		$6.26M Buy
1,672,493
+152,232
+10% +$729K ﹤0.01% 3636
2024
Q3 		$7.43M Buy
1,520,261
+66,594
+5% +$513K ﹤0.01% 3555
2024
Q2 		$10.9M Buy
1,453,667
+703,701
+94% +$10.8M ﹤0.01% 3342
2024
Q1 		$18.6M Buy
+749,966
New +$20.9M ﹤0.01% 3030

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $207M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.32B AUM 1.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BlackRock's KYTX Position: Q2 2026 in Review

BlackRock increased its Kyverna Therapeutics (KYTX) stake by 257% in Q2 2026, buying an estimated $20M and bringing the position to 3,134,807 shares worth $27.9M. The position accounts for ﹤0.01% of the portfolio, ranked #3046.

BlackRock first reported a position in KYTX in Q1 2024 and has held it in 10 quarters since. 120 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • BlackRock held 3,134,807 shares of Kyverna Therapeutics worth $27.9M as of Q2 2026.
  • BlackRock bought 2,257,729 Kyverna Therapeutics shares in Q2 2026, an estimated $20M.
  • Kyverna Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #3046 holding.
  • BlackRock first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 10 quarters since.
  • 120 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.